| Prognostic effect of systemic immune cells on anti-PD-1 antibody therapy in patients with advanced urothelial bladder cancer |
| Received:July 06, 2022 Revised:January 17, 2023 Click here to download the full text |
| Citation of this paper:LIN Zhi-yuan,LU Li-li,CHEN Pu,GUO Jian-ming,JIANG Shuai.Prognostic effect of systemic immune cells on anti-PD-1 antibody therapy in patients with advanced urothelial bladder cancer[J].Chinese Journal of Clinical Medicine,2023,30(1):49-55 |
| Hits: 1134 |
| Download times: 326 |
| Author Name | Affiliation | E-mail | | LIN Zhi-yuan | Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | LU Li-li | Biotherapy Centre, Zhongshan Hospital, Fudan University, Shanghai 200032, China
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China 4. Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | CHEN Pu | | | | GUO Jian-ming | Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | | | JIANG Shuai | Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China | jiang.shuai@zs-hospital.sh.cn |
|
| Abstract:Objective To explore the predictive effect of systemic immune cells on anti-programmed cell death protein 1 (PD-1) antibody therapy in patients with advanced urothelial bladder cancer (UBC). Methods We retrospectively analyzed 86 patients with advanced UBC who received anti-PD-1 antibody therapy. Clinical information, systemic immune cell data and tumor PD-1/programmed cell death ligand 1 (PD-L1) expression status were collected. The influence of these indicators on patient survival and objective response rate (ORR) were analyzed. Results Early TNM stage (P=0.02), high systemic NK cells (P=0.009), high ratio of CD4＋T in T lymphocytes (CD4＋T%, P=0.009) and high B lymphocytes (P=0.038) were independent prognostic factors for good overall survival (OS). Patients with early TNM stage (P＜0.001), high systemic NK cells (P=0.043) and high B lymphocytes (P=0.027) were independent prognostic factors of good progression free survival (PFS). Patients with high systemic B lymphocytes (P=0.011), high CD4＋T% (P=0.041) and high total lymphocytes (P＜0.001) had higher ORR for anti-PD-1 antibody therapy. Conclusions In this study, systemic NK cells, B lymphocytes and CD4＋T cells of advanced UBC patients may play an important role in anti-tumor immunity. Systemic B lymphocytes, CD4＋T% and total lymphocytes affected the ORR of patients treated with anti-PD-1 antibody, and may be involved in the therapeutic process of anti-PD-1 treatment. |
| keywords:urothelial bladder cancer PD-1 B lymphocyte NK cell CD4＋T cell |
| HTML View Full Text View/Add Comment Download reader |
|
|
|